Transplantation proceedings · 2025
Meta-Analysis and Clinical Guidance of Oxygenated Hypothermic Machine Perfusion for Kidney Transplantation.
СтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jia Degong, Guo Shanshan, Luo Jiefu, Zhang Yuezhou, Zhang Huiqing, Shengwei, Liu Junyan
Аннотация
BACKGROUND: It remains unclear whether oxygenated hypothermic machine perfusion (HMPO2) during kidney preservation is beneficial for prognosis.
METHODS: A comprehensive search of databases and clinical trial registries was conducted to identify eligible studies on HMPO2 application during kidney transplantation. A multisubgroup analysis was further conducted to explore the heterogeneity among studies.
RESULTS: Compared to the control treatment, HMPO2 did not significantly alter the incidence of postoperative acute rejection, graft survival, patient mortality, delayed graft function (DGF), functional DGF, primary nonfunction, or estimated glomerular filtration rate, whereas the warm ischemia time appeared to be longer. However, the number of patients with adverse events and the proportion of severe adverse events were reduced in the HMPO2 group. Subgroup analysis indicated that HMPO2 performed better in donation after cardiac death (DCD), and continuous HMPO2 was superior to end-HMPO2.
CONCLUSION: HMPO2 application during kidney transplantation reduced the number of patients with adverse events and the proportion of severe adverse events. However, given the issue such as limited number of studies and heterogeneity, rigorous evidence studies are needed to further confirm these findings.
METHODS: A comprehensive search of databases and clinical trial registries was conducted to identify eligible studies on HMPO2 application during kidney transplantation. A multisubgroup analysis was further conducted to explore the heterogeneity among studies.
RESULTS: Compared to the control treatment, HMPO2 did not significantly alter the incidence of postoperative acute rejection, graft survival, patient mortality, delayed graft function (DGF), functional DGF, primary nonfunction, or estimated glomerular filtration rate, whereas the warm ischemia time appeared to be longer. However, the number of patients with adverse events and the proportion of severe adverse events were reduced in the HMPO2 group. Subgroup analysis indicated that HMPO2 performed better in donation after cardiac death (DCD), and continuous HMPO2 was superior to end-HMPO2.
CONCLUSION: HMPO2 application during kidney transplantation reduced the number of patients with adverse events and the proportion of severe adverse events. However, given the issue such as limited number of studies and heterogeneity, rigorous evidence studies are needed to further confirm these findings.